UPDATE: Milestone Pharmaceuticals (MIST) - Express Scripts Says Yes, and the Stock Wakes Up

The biggest commercial bear argument just got neutered. Plus a real-world evidence registry that smells like an M&A grooming move.

The stock ran +39% from $1.36 on March 20 to $1.89 on April 24, and it isn’t because of the Needham conference invite. On March 31, CARDAMYST landed on Express Scripts’ Commercial National Formularies — one of the three PBMs that gatekeep U.S. drug access. Then on April 10, Milestone announced the RESET-PSVT real-world evidence registry. Both items chip directly at the bear case I laid out in December. Thesis is tracking.